Chris Murphy actually said...

"If we are successful in getting this pathway to biosimilars moving then my fear is with a product sitting on the market that could cost 30 percent less we are going to be behind this avalanche of phar..."

"We can do all of this work on trying to make sure that we approve biosimilars, but if they're not actually getting prescribed, if we aren't giving FDA the resources to make the case that they should b..."

"This increased cost is born by our healthcare system as a whole, but more specifically by patients as more and more insurance companies place higher cost sharing burdens on biologics."

"I hope that we can talk about that today."